Modern management of acute myocardial infarction

Current Problems in Cardiology

Volumn 21, Issue 9, 1996, Pages 585-667

  Reeder, Guy S ^a   Gersh, Bernard J ^b  

^a MAYO CLINIC   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2442615450     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0146-2806(96)80003-X     Document Type: Review

References (152)

1. Heart and Stroke Facts: 1994 Statistical Supplement. American Heart Association 1994:1-22.
2. Norris RM. The changing natural history and prognosis of acute myocardial infarction. In: Gersh BJ, Rahimtoola SH, editors. Acute myocardial infarction (current topics in cardiology). New York: Elsevier Science, 1991:87-97.
3. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
4. Willich SN, Linderer T, Wegscheider K, et al. Increased morning incidence of myocardial infarction in the ISAM study: absence with prior β-adrenergic blockade. Circulation 1989;80:853-8.
5. Kono T, Morita H, Nishina T, et al. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. J Am Coll Cardiol 1996;27:774-8.
6. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-73.
7. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-4.
8. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
9. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implication for plaque rupture. Circulation 1994;90:775-8.
10. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
11. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995;332:677-8.
12. Gibson RS. Non-Q-wave myocardial infarction: diagnosis, prognosis, and management. Curr Probl Cardiol 1988;13:1-72.
13. Bayer AJ, Chadha J, Farag RR, et al. Changing presentation of myocardial infarction with increasing old age. J Am Geriatr Soc 1986;34:263-6.
14. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-64.
15. Hands ME, Cook EF, Stone PH, et al. Electrocardiographic diagnosis of myocardial infarction in the presence of complete left bundle branch block. Am Heart J 1988;116:23-30.
16. Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med 1996;334:481-7.
17. Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994;331:561-6.
18. Thomson SP, Gibbons RJ, Smars PA, et al. Incremental value of the leukocyte differential and rapid creatine kinase-MB isoenzyme for the early diagnosis of myocardial infarction. Ann Intern Med 1995;122:335-41.
19. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin Chem 1995;41:1266-72.
20. Wu AHB, Lane PL. Meta-analysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart disease. Clin Chem 1995;41:1228-33.
21. Ravkilde J, Nissen H, Horder M, Thygesen K. Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction: analysis of 28 months of follow-up in 196 patients. J Am Coll Cardiol 1995;25:574-81.
22. Christian TF, Gibbons RJ, Gersh BJ. Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile. J Am Coll Cardiol 1991;17:1303-8.
23. Barilla F, Gheorghiade M, Alam M, et al. Low-dose dobutamine in patients with acute myocardial infarction identifies viable but not contractile myocardium and predicts the magnitude of improvement in wall motion abnormalities in response to coronary revascularization. Am Heart J 1991;122:1522-31.
24. Reeder GS. Identification and treatment of complications of myocardial infarction. Mayo Clin Proc 1995;70:880-4.
25. Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemia cell death. I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-94.
26. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemia cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-44.
27. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
28. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
29. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
30. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
31. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
32. Simoons ML, Arnold ER. Tailored thrombolytic therapy: a perspective. Circulation 1993;88:2556-64.
33. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 1996;93:857-65.
34. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm - paradoxic or predictable? Circulation 1993;88:296-306.
35. Weaver WD, Cerqueria M, Hallstrom AP, et al., for the Myocardial Infarction Triage and Intervention Project Group. Prehospital-initial vs hospital-initiated thrombolytic therapy. JAMA 1993;270:1211-16.
36. Edward F, Ellerbeck MD, Stephen F, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA 1995;273:1509-14.
37. O'Neill W, Timmis GS, Bourdillon PD, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986;314:812-8.
38. DeWood MA, Fisher MJ, for the Spokane Heart Research Group. Direct PTCA versus intravenous rtPA in acute myocardial infarction: preliminary results from a prospective randomized trial. Circulation 1989;80(suppl II):II-418.
39. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-9.
40. Zjilstra F, Jan de Boer M, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.
41. De Boer M, Hoorntje J, Suryapranata H, Zijlstra F. Coronary angioplasty results in a lower rate of recurrent infarction and death when compared with streptokinase in patients with a myocardial infarction. Circulation 1993;88(I Suppl):I-106.
42. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-91.
43. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376-80.
44. Elizaga J, Garcia EJ, Delcan JL, et al. Primary coronary angioplasty versus systemic thrombolysis in acute anterior myocardial infarction: in-hospital results from a prospective randomized trial. Circulation 1993;88(I Suppl):I-411.
45. Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-51.
46. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-1 Trial Experience. J Am Coll Cardiol 1995;26: 668-74.
47. Hochman J, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995;91:873-81.
48. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995;91:476-85.
49. Reeder GS, Bailey KR, Gersh BJ, Holmes DR, Christianson J, Gibbons RJ. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Clin Proc 1994;69:5-12.
50. Berger PB, Bell MR, Holmes DR Jr, Gersh BJ, Hopfenspirger M, Gibbons RJ. Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1994;73:231-6.
51. Jhangiani AH, Jorgensen MB, Prakash WM, et al. Community practice of primary angioplasty for myocardial infarction. J Am Coll Cardiol 1996;27:61A.
52. Mercho N, Eldin AM, Shareef B, Glazier JJ, et al. Angiographic complications of primary angioplasty. J Am Coll Cardiol 1996;27:61A.
53. Cannon CP, Lambrew CT, Tiefenbrunn AJ, et al. Influence of door-to-balloon time on mortality in primary angioplasty results in 3,648 patients in the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1996;27:61A.
54. Neuhaus KL, Vogt A, Harmjanz D, et al. Primary PTCA in acute myocardial infarction: results from a German Multicenter registry. J Am Coll Cardiol 1996;27:62A.
55. Patel S, Reese C, O'Connor RE, Doorey AJ. Adverse outcomes accompanying primary angioplasty (PTCA) for acute myocardial infarction (AMI) - dangers of delay. J Am Coll Cardiol 1996;27:62A.
56. Caputo RP, Lopez JJ, Stoler RC, et al. The effect of institutional experience on the outcome of primary angioplasty for acute MI. J Am Coll Cardiol 1996;27:62A.
57. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.
58. Simoons ML, Arnold AER, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
59. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-27.
60. Topol EJ, Califf RM, George BS, et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 1988;77:1100-7.
61. Ellis SG, da Silva ER, Heyndrickx G, for the RESCUE Investigators. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90:2280-4.
62. Puleo PR, Perryman MB, Bresser MA, et al. Creatine kinase isoform analysis in the detection and assessment of thrombolysis in man. Circulation 1987;75:1162-9.
63. Langer A, Krucoff MW, Klootwijk P, et al. Non-invasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST Segment Monitoring Study. J Am Coll Cardiol 1995;25:1552-7.
64. De Bono DP, Pocock SJ, for the SWIFT Investigators Group. The SWIFT study of intervention versus conservative management after anistreplase thrombolysis [abstract]. Circulation 1989;80(4 Suppl):II-418.
65. Ellis SG, Mooney MR, George BS, et al. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction: Treatment of Post-Thrombolytic Stenoses (TOPS) study group. Circulation 1992;86:1400-6.
66. Topol EJ, Holmes DR, Rogers WJ. Coronary angiography after thrombolytic therapy for acute myocardial infarction. Ann Intern Med 1991;114:877-85.
67. Reiner JS, Lundergan CF, van den Brand M, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. J Am Coll Cardiol 1994;24:1439-44.
68. Jugdutt BI, Becker LC, Hutchins GM, et al. Effect of intravenous nitroglycerin on collateral blood flow and infarct size in the conscious dog. Circulation 1981;63:17-28.
69. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation 1988;78:906-19.
70. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988;1: 1088-92.
71. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
72. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
73. Woods KL. Mega-trials and management of acute myocardial infarction. Lancet 1995;346:611-14.
74. β-Blocker Heart Attack Study Group. The β-Blocker Heart Attack Trial. JAMA 1981;246:2073-4.
75. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
76. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
77. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984;310:9-15.
78. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1988;1:921-3.
79. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo-controlled international trial. Eur Heart J 1985;6:199-211.
80. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54.
81. Held PH, Yusuf S, Furberg CO. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989;299:1187-92.
82. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized multicenter trial. N Engl J Med 1986;315:423-9.
83. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
84. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected myocardial infarction: an overview of results from randomized, controlled trials. JAMA 1988;260:1910-16.
85. Hearse DJ, Stewart DA, Braimbridge MHV. Myocardial protection during ischaemic cardiac arrest. J Thorac Cardiovasc Surg 1978;75:877-85.
86. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991;303:1499-1503.
87. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-8.
88. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994;343:816-9.
89. Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995;75:321-3.
90. Antman EM. Magnesium in acute MI. Circulation 1995;92:2367-72.
91. Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 1995;92:2617-21.
92. Herzog WR, Schlossberg ML, MacMurdy KS. Timing of magnesium therapy affects experimental infarct size. Circulation 1995;92:2622-6.
93. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
94. Lonn EM, Yusuf S, Prabhat J, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
95. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H, for the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327:678-84.
96. Chinese Cardiac Study Collaboratory Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
97. Pfeffer MA, Braunwald E, Moyé LA, et al. for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med 1992;327:669-77.
98. The TRACE Study Group. The Trandolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994;73:44C-50C.
99. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
100. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) study investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
101. Kingma JH, Van Gilst WH, Peels CH, Dambrink JHE, Verbeugt FWA, Wielenga RP. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction: results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994;15:898-907.
102. Connolly DC, Elveback LR. Coronary heart disease in residents of Rochester, Minnesota. III. Hospital and posthospital course of patients with transmural and subendocardial myocardial infarction. Mayo Clin Proc 1985;60:375-81.
103. Hutter AM Jr, DeSanctis RW, Flynn T, et al. Nontransmural myocardial infarction: a comparison of hospital and late clinical course of patients with that of matched patients with anterior and transmural inferior myocardial infarction. Am J Cardiol 1981;48:595-602.
104. Gibson RS. Non-Q-wave myocardial infarction: prognosis, changing incidence, and management. In: Gersh BJ, Rahimtoola SH, eds. Acute myocardial infarction (current topics in cardiology). New York: Elsevier Science, 1991:284-307.
105. The TIMI-IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI-IIIB trial. Circulation 1994;89:1545-56.
106. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB Clinical Trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
107. Aguirre FV, Younis LT, Chaitman BR, et al. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis: results from the TIMI-II study. Circulation 1995;91:2541-8.
108. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991;325:1117-22.
109. Forrester JH, Diamond G, Chatterjee K, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976;295: 1356-62.
110. Ratshin RA, Rackley CE, Russell RO Jr. Hemodynamic evaluation of left ventricular function in shock complicating myocardial infarction. Circulation 1972;45:127-39.
111. Nishimura RA, Tajik AJ, Shub C, et al. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol 1984;4:1080-7.
112. Nishimura RA, Schaff HV, Gersh BJ, et al. Early repair of mechanical complications after acute myocardial infarction. JAMA 1986;256:47-50.
113. Montoya A, McKeever L, Scanlon P, et al. Early repair of ventricular septal rupture after infarction. Am J Cardiol 1980;45:345-8.
114. Radford MJ, Johnson RA, Daggett WM Jr, et al. Ventricular septal rupture: a review of clinical and physiologic features and an analysis of survival. Circulation 1981;64:545-53.
115. Nishimura RA, Schaff HV, Shub C, et al. Papillary muscle rupture complicating acute myocardial infarction: analysis of 17 patients. Am J Cardiol 1983;51:373-7.
116. López-Sendón J, González A, López de Sá E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. J Am Coll Cardiol 1992;19:1145-53.
117. Parry G, Goudevenos J, Adams PC, et al. Septal rupture after myocardial infarction: is very early surgery really worthwhile? Eur Heart J 1992;13:373-82.
118. Batts KP, Ackermann DM, Edwards WD. Postinfarction rupture of the left ventricular free wall: clinicopathologic correlates in 100 consecutive autopsy cases. Hum Pathol 1990;21:530-5.
119. Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992;70:147-51.
120. John JN, Guiha NH, Broder MI, et al. Right ventricular infarction: clinical and hemodynamic features. Am J Cardiol 1974;33:209-14.
121. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
122. Goodfellow J, Walker PR. Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with streptokinase. Eur Heart J 1995;16:862-5.
123. Goldberg RJ, Zevallos JC, Yarzebski J, et al. Prognosis of acute myocardial infarction complicated by complete heart block (the Worcester Heart Attack Study). Am J Cardiol 1992;69:1135-41.
124. Clemmensen P, Bates ER, Califf RM, et al. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. Am J Cardiol 1991;67:225-30.
125. Berger PB, Ruocco NA Jr, Ryan TJ, et al. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI-II. J Am Coll Cardiol 1992;20:533-40.
126. Behard S, Zissman E, Zion M, et al. Complete atrioventricular block complicating inferior acute wall myocardial infarction: short- and long-term prognosis. Am Heart J 1993;125:1622-7.
127. DeGuzman M, Rahimtoola SH. What is the role of pacemakers in patients with coronary artery disease and conduction abnormalities? Cardiovasc Clin 1983;13(1):191-207.
128. The Cardiac Arrhythmia Suppression Trial Investigators (CAST). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
129. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-8.
130. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991;84:550-7.
131. Gomes JA, Winters SL, Stewart D, et al. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987;10:349-57.
132. Sanz G, Castañer A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med 1982;306:1065-70.
133. ACC/AHA guidelines for the early management of patients with acute myocardial infarction [special report]. Circulation 1990;82:664-707.
134. Hine LK, Laird NM, Hewitt P, et al. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989;262:3037-40.
135. The Cardiac Arrhythmia Suppression Trial Investigators (CAST). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
136. Akhtar M, Breithardt G, Camm AJ, et al. CAST and beyond: implications of the Cardiac Arrhythmia Suppression Trial. Circulation 1990;81:1123-7.
137. Pfisterer M, Kiowski W, Burckhardt D, et al. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992;69:1399-1402.
138. Murdaugh CL, O'Rourke RA. Coronary heart disease in women: special considerations. Curr Probl Cardiol 1988;13:73-156.
139. Kannel WB, Abbott RD. Incidence and prognosis of myocardial infarction in women: the Framingham Study. In: Wenger NK, editor. Coronary heart disease in women: proceedings of an NIH workshop. New York: Haymarket Doyma, 1987:208-14.
140. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987;9:473-82.
141. Vaccarino V, Krumholz HM, Berkman LF, Horwitz RI. Sex differences in mortality after myocardial infarction: is there evidence for an increased risk for women? Circulation 1995;91:1861-71.
142. Weaver WD, White HD, Wilcox RG, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA 1996;275:777-82.
143. Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986;58:1151-60.
144. Denniss AR, Richards DA, Cody DV, et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986;74:731-45.
145. Vatterott PJ, Hammill SC, Bailey KR, et al. Signal-averaged electrocardiography: a new noninvasive test to identify patients at risk for ventricular arrhythmias. Mayo Clin Proc 1988;63:931-42.
146. Odemuyiwa O, Farrell TG, Malik M, et al. Influence of age on the relation between heart rate variability, left ventricular ejection fraction, frequency of ventricular extrasystoles, and sudden death after myocardial infarction. Br Heart J 1992;67:387-91.
147. Gomes JA, Winters SL, Martinson M, et al. The prognostic significance of quantitative signal-averaged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: a prospective study. J Am Coll Cardiol 1989;13:377-84.
148. Hillis LD, Forman S, Braunwald E, Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990;16:313-5.
149. Lee KL, Woodlief MS, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
150. Volpi A, de Vita C, Grazia Franzosi M, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of the GISSI-2 data base. Circulation 1993;88:416-29.
151. Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic era: analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Trial. J Am Coll Cardiol 1996;27:625-32.
152. Reeder GS, Gibbons RJ. Acute myocardial infarction: risk stratification in the thrombolytic era. Mayo Clin Proc 1995;70:87-94.